The Relationship of Methylated Arginines with Urine Cadmium Levels

Oztan O., TÜRKSOY V. A., Deniz S., Iritas S. B., Tutkun E.

Clinical Laboratory, vol.68, no.1, pp.70-77, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 68 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.7754/clin.lab.2021.210504
  • Journal Name: Clinical Laboratory
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.70-77
  • Keywords: Cd exposure, CdU, methylated arginines, atherosclerotic cardiovascular diseases
  • Ankara Yıldırım Beyazıt University Affiliated: Yes


© 2022 Verlag Klinisches Labor GmbH. All rights reserved.Background: In this study, we aimed to show that methylated arginines are the predictors of non-clinical athero-sclerotic cardiovascular complications in metal workers exposed to Cd. Methods: The 80 Cd-exposed metal workers and 80 non-exposed workers (control) included in the study were available for measuring arginine, ADMA, SDMA, and L-NMMA levels. Results: The average urine Cd levels (CdU) found were 1.03 ± 0.8 μg/g creatinine (0.84 ± 0.65 μg/L) ranging from 0.01 to 3.00 μg/g creatinine in the control group and 5.41 ± 5.2 μg/g creatinine (4.29 ± 3.81 μg/L) ranged from 0.11 to 27.2 μg/g creatinine in metal workers. On the other hand, the median ratios of the different groups (exposed and control) were found to be 449.35 and 483.88 for arginine/ADMA and 1.28 and 1.33 SDMA/ADMA, respective-ly. Conclusions: The present study was undertaken to investigate the relationship between cadmium exposure and methylated arginines such as ADMA/SDMA/L-NMMA parameters which is important for the early detection ath-erosclerotic cardiovascular diseases.